Extended indication

MINJUVI is indicated in relapsed/ refractory follicular and marginal zone lymphoma in combination wi

Therapeutic value

No estimate possible yet

Registration phase

Clinical trials

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information